The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Someone on this board recently confidently asserted (contrary to company communication) that LPLDL wasn't a replacement for statins.
The recent tweet by Cholbiome would confirms this was incorrect https://twitter.com/CholBiome/status/1492103653007802369
Here is a link to one of Dr Ranj's appearances yesterday. https://open.spotify.com/episode/72wv2uqv9bhaYnku58KReh
Skid, we need to stick to the facts indeed. LPLDL is not a new product, and it is not a drug (it is a food supplement), so it would not be subject to a multi phase clinical trial as you suggest. It has already passed all the requisite safetly, tolerability and efficacy trials that would be typical of a phase 1 and 2 study some years ago. So yes, these results can be regarded as a proper clinical trial. The company has also indicated from previous releases that it is also exploring moving LPLDL along the pharmaceutical route in addition to over the counter.
The presentation is here: https://www.youtube.com/watch?v=j5WW9Geo0rg&t=1863s
18.60 equivalent buys on ASX last night, yours for 16.75 this morning. Somehow the dip in U3O8 equities overnight shaken off in this share
Belgrano have you read all of the RNS? Options can only be exercised when certain performance criteria are met. Which at present, they haven't. So there won't be any exercised or sold until those milestones are reached
Bottom line is that share options (=dilution) have been halved. If this had been some tin-point gravy train oil explorer then maybe some critiscism could be justified. But the OPTI directors in my opinion are not of that ilk, and I beleive they add significant value to the company. The reasons given in the RNS are fair. I'm not going to begrudge them a reasonable milestone-based incentive.
Seems reasonable to me. These aren't massive swathes of shares in the scheme of things, and as stated they reduce the total number of options in issue against perfectly reasonable vesting targets. Bring on the Sweetbiotix news...
Anthony V has indicated to investors by private communication that he expects the phase 2 finance to be by debt only. They are not looking to raise new equity. Would suggest anyone with questions like these email the company directly as they are happy to respond to investors.